Genpharm Services, LifeCodexx and Biogen Medical announce distribution agreements to make PrenaTest® available in Turkey and in the Middle – East.
LifeCodexx AG, a German life science company focusing on the development of clinically validated molecular diagnostic tests based on the use of next generation sequencing techniques, has agreed to collaborate with BioGen Medical and Genpharm Services for the commercialisation and distribution of PrenaTest® in Turkey, the Middle East and Gulf regions (United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, Bahrain, Oman, Qatar). PrenaTest® is an innovative non-invasive molecular genetic blood test for the detection of fetal trisomy 21 from maternal blood.
The completion of the agreement with BioGen Medical and Genpharm Services marks LifeCodexx’s first commercial partnership in the field of non-invasive prenatal diagnostics in this region. Under the terms of this agreement, Biogen Medical and Genpharm Services will register and commercialize PrenaTest® in Turkey and the Middle East respectively.
“We are very excited to launch the first and so far only non-invasive, molecular genetic, prenatal test in Turkey which has proven its effienciency in terms of the IVD directive of the European Union. We will be able to save many mothers from invasive procedures like amniocentesis, as well as from procedure related fetal losses and complications. said Dr. Sanli ERKAN, Medical Director of BioGen Medical.
“We are delighted to partner with both LifeCodexx and BioGen Medical, in making PrenaTest® available to mothers across our region. Prenatest® is a great addition to our portfolio. We will work closely with all stakeholders, register and launch Prenatest® through scientific education and evidence based communication. We are proud to make Prenatest® available in the region, shortly after its successful launch in Europe”, concluded Karim Smaira, CEO of Genpharm Services.
“Many women with risk pregnancies for fetal aneuploidies such as trisomy 21 have a strong interest in the PrenaTest®. This is what we learned since we launched the test three months ago. Together with our clinical partners we are now able to provide our non-invasive molecular genetic blood test to these women in their own countries,” said Dr. Michael Lutz, CEO of LifeCodexx AG.
PrenaTest® is the only non-invasive molecular genetic blood test for the detection of fetal trisomy 21 in Europe, which has successfully completed the conformity assessment procedures required for CE marking, thus proven its efficiency in terms of the in-vitro diagnostics directive of the European Union. In the first three months after market launch in August 2012, around 1,000 PrenaTest analyses had already been carried out. Beginning of 2013 LifeCodexx’ blood test will be able to detect trisomy 13 and 18, too
Genpharm Services is a pharmaceutical marketing company, based in the Dubai Biotechnology and Research Park, UAE. Through evidence-based medicine, Genpharm provides healthcare organizations with innovative therapeutic solutions in niche and rare genetic disease areas, market access strategies and sustainable commercial solutions in the Middle East and North Africa Region.For more information, please visit www.genpharmservices.com
|Karim Smaira Chief Executive Officer firstname.lastname@example.org +971 4 422 70 10||Ashwathy Anil BusinessDevelopment Ashwathy@genpharmservices.com +971 4 422 70 10|